Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Safety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Dose of YY524051 Tablets in Healthy Adults.

13 de novembro de 2026 atualizado por: Beijing Baheal Wisart Medical Research Co., Ltd

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral YY524051 Tablets in Healthy Participants

This is a Phase 1 study to evaluate the safety, tolerability, and how the body processes an investigational drug called YY524051 tablets in healthy participants.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

This is a single-center Phase 1, randomized, double-blind, placebo controlled, first-in-human (FIH) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of an investigational drug called YY524051 tablets in healthy adult participants.

The study is divided into two parts:

Single Ascending Dose (SAD) part: Participants will receive a single dose of the drug to see how the body handles it and to determine a safe dose level. A staggered dosing schedule will be used, where a few "sentinel" participants will be dosed first to ensure safety before the rest of the cohort receives the drug. A food-effect (FE) assessment will be nested at a selected dose level after fasting dosing during escalation, and a clinical QT/QTc (CQTc) assessment will be embedded within selected SAD cohorts.

Multiple Ascending Dose (MAD) part: Participants will take the drug repeatedly over several days to assess accumulation and steady-state in the body and to further evaluate its safety.

Participants will be randomly assigned to receive either YY524051 tablets or a placebo (placebo tablet containing no active ingredient). The study is "double-blind," meaning neither the participants nor investigators will know who is receiving the real drug.

The information gathered from this study will help researchers understand the best way to give this drug, characterize its PK profile, and determine a safe dose for future studies in patients.

Tipo de estudo

Intervencional

Inscrição (Estimado)

78

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Beijing, China
        • Peking University Third Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 45 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Participants must meet ALL of the following criteria to be eligible for enrollment:

  • Healthy participants, male or female (the ratio of males to females will be kept as balanced as possible).
  • Age between 18 and 45 years (inclusive). Body weight ≥ 50 kg for males and ≥ 45 kg for females. Body Mass Index (BMI) between 19.0 and 28.0 kg/m² (inclusive). BMI = weight (kg) / height² (m²).
  • Able to understand the informed consent form, and voluntarily participate and sign the informed consent form.

Exclusion Criteria:

Participants who meet ANY of the following criteria will be excluded from the study:

  • History of drug allergy, or known allergy to the investigational product or any of its excipients (microcrystalline cellulose, mannitol, croscarmellose sodium, povidone, magnesium stearate, film coating premix (gastric-soluble), sodium stearyl fumarate, lactose);
  • History of or current clinically significant diseases in the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, or metabolic systems, as determined by the investigator;
  • History of drug addiction; history of alcohol abuse within 6 months prior to screening (defined as consuming more than 14 standard units of alcohol per week [1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine]); average daily cigarette consumption ≥ 5 cigarettes within 3 months prior to screening; positive urine drug screen or positive alcohol breath test at screening; or inability to comply with the prohibition of smoking/alcohol during the study period;
  • History of cardiovascular or cerebrovascular surgery; history of any surgery affecting drug absorption, distribution, metabolism, or excretion; severe trauma or surgery within 6 months prior to screening; or planned surgery during the study period;
  • Positive results for any of the following: Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCVAb), Treponema pallidum particle agglutination (TPPA), or Human Immunodeficiency Virus (HIV) antibody;
  • Positive pregnancy test for female participants;
  • Breastfeeding female participants; female participants who refuse to use effective non-pharmacological contraceptive measures (e.g., abstinence, intrauterine device) or have egg donation plans from signing the informed consent until 90 days after the last dose; male participants who refuse to commit to no reproductive or sperm donation plans or refuse to use effective physical contraceptive measures, or have sperm donation plans from signing the informed consent until 90 days after the last dose;
  • Abnormalities in physical examination, laboratory tests, vital signs, echocardiography, abdominal ultrasound, or chest X-ray that are clinically significant as determined by the investigator and may affect the evaluation of study endpoints;
  • Blood pressure ≥ 140/90 mmHg or < 90/50 mmHg; heart rate < 50 beats/min or > 100 beats/min;
  • Clinically significant abnormalities on 12-lead electrocardiogram (ECG) as determined by the investigator, including: Prolonged QT interval: QTcF > 450 msec (males) or > 470 msec (females); PR interval > 200 msec; QRS interval > 120 msec;
  • Consumption of excessive tea, coffee, or caffeine-containing beverages (≥ 8 cups per day, 1 cup = 250 mL) daily within 3 months prior to screening; or habitual consumption of any xanthine-rich beverages or foods (e.g., caffeine, theophylline, theobromine) or fruits/foods affecting metabolic enzymes (e.g., grapefruit, pomelo, starfruit, mango) that cannot be abstained from during the study period;
  • Special dietary requirements or inability to comply with a standardized diet;
  • Difficulty swallowing tablets;
  • Inability to tolerate venipuncture, history of hemophobia/needle phobia, or poor vascular conditions making blood collection difficult;
  • Use of any drugs that inhibit or induce hepatic drug-metabolizing enzymes within 28 days prior to screening; or use of any prescription drugs, over-the-counter drugs, herbal medicines, or dietary supplements within 2 weeks (or 5 half-lives, whichever is longer) prior to screening;
  • Participation in any clinical trial within 3 months prior to screening; or still within 5 half-lives of an investigational drug from a previous clinical trial at screening;
  • History of blood donation or significant blood loss (≥ 400 mL) within 3 months prior to screening or between screening and first dose; history of blood transfusion within 3 months; or plans to donate blood during the study period;
  • Poor compliance or any other conditions that make the participant unsuitable for the study as judged by the investigator.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Placebo

Matching placebo tablets will be administered orally to participants in the control groups. In the SAD phase (initially planned up to 5 cohorts), a single dose will be given once in the morning under fasting conditions. In the MAD phase (initially planned up to 3 cohorts), placebo will be administered once daily in the morning for 7 consecutive days. The actual number of cohorts may be adjusted based on the safety and tolerability data reviewed by the Safety Review Committee (SRC)

Matching placebo.

Experimental: YY524051 tablets

YY524051 tablets will be administered orally to participants in the treatment groups. In the SAD phase (initially planned up to 5 cohorts), single ascending doses will be given once in the morning under fasting conditions. In the MAD phase (initially planned up to 3 cohorts), multiple ascending doses will be administered once daily in the morning for 7 consecutive days. The actual number of cohorts and dose levels may be adjusted based on the safety and tolerability data reviewed by the Safety Review Committee (SRC).

YY524051 tablets administered orally

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence, severity, and causality of adverse events (AEs) and serious adverse events (SAEs)
Prazo: SAD: Day1 to Day 8 MAD: Day1 to Day 14

Safety and Tolerability as assessed by AEs and SAEs

SAD: Day1 to Day 8 MAD: Day1 to Day 14

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Tmax
Prazo: Pre-dose to 48 hours post-dose

Peak time: The time required to reach peak concentration after administration

Pre-dose to 48 hours post-dose
Cmax
Prazo: Pre-dose to 48 hours post-dose

Peak concentration: The highest blood concentration after administration

Pre-dose to 48 hours post-dose
AUC
Prazo: Pre-dose to 48 hours post-dose

Area under the drug time curve: The area surrounded by the blood concentration curve to the time axis.

Pre-dose to 48 hours post-dose
t1/2
Prazo: Pre-dose to 48 hours post-dose

Terminal elimination half-life: The time required for the terminal phase blood concentration to decrease by half

Pre-dose to 48 hours post-dose

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2027

Conclusão do estudo (Estimado)

1 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

13 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • YY524051-I-01
  • CTR20264102 (Outro identificador: CDE,NMPA)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever